Get the Stockscreener App
189.23
0.25%
0.48
Revolution Medicines Inc stock is traded at $189.23, with a volume of 1.29M.
It is up +0.25% in the last 24 hours and up +11.46% over the past month.
Revolution Medicines Inc is a clinical-stage precision oncology company developing novel targeted therapies for RAS-addicted cancers. The Company possesses structure-based drug discovery capabilities built upon chemical biology and cancer pharmacology know-how and proprietary technologies that enable the creation of small molecules tailored to unconventional binding sites. Its research and development pipeline comprises inhibitors that bind directly to RAS variants (RAS(ON) Inhibitors), designed to be used as monotherapy, in combination with other RAS(ON) Inhibitors and/or other therapeutic agents.
See More
Previous Close:
$188.75
Open:
$189.23
24h Volume:
1.29M
Relative Volume:
0.45
Market Cap:
$40.23B
Revenue:
$742.00K
Net Income/Loss:
$-1.37B
P/E Ratio:
-26.75
EPS:
-7.0731
Net Cash Flow:
$-1.07B
1W Performance:
+1.65%
1M Performance:
+11.46%
6M Performance:
+60.87%
1Y Performance:
+408.41%
1-Day Range:
$185.89
$190.50
1-Week Range:
$179.39
$193.53
52-Week Range:
$34.00
$193.82
Revolution Medicines Inc Stock (RVMD) Company Profile
Name
Revolution Medicines Inc
Sector
Industry
Phone
650-481-6801
Address
700 SAGINAW DR, REDWOOD CITY, CA
Compare RVMD vs VRTX, REGN, ARGX, ALNY
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
RVMD
Revolution Medicines Inc
|
189.23 | 40.23B | 742.00K | -1.37B | -1.07B | -7.0731 |
VRTX
Vertex Pharmaceuticals Inc
|
477.36 | 121.16B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
656.01 | 68.78B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
918.22 | 57.44B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
271.77 | 36.28B | 4.29B | 577.22M | 641.34M | 4.2086 |
Revolution Medicines Inc Stock (RVMD) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-16-26 | Resumed | Jefferies | Buy |
| Feb-27-26 | Resumed | UBS | Buy |
| Nov-18-25 | Initiated | Wolfe Research | Outperform |
| Nov-03-25 | Initiated | RBC Capital Mkts | Outperform |
| Oct-21-25 | Initiated | Mizuho | Outperform |
| Oct-16-25 | Resumed | Stifel | Buy |
| Sep-12-25 | Resumed | Raymond James | Strong Buy |
| Sep-05-25 | Initiated | Truist | Buy |
| Aug-19-25 | Initiated | Piper Sandler | Overweight |
| Aug-15-25 | Initiated | Wells Fargo | Overweight |
| Jul-15-25 | Initiated | Goldman | Buy |
| Jul-16-24 | Reiterated | Needham | Buy |
| Jul-12-24 | Initiated | Barclays | Overweight |
| Jul-08-24 | Initiated | Jefferies | Buy |
| Apr-12-24 | Reiterated | Needham | Buy |
| Apr-10-24 | Upgrade | Raymond James | Outperform → Strong Buy |
| Mar-11-24 | Initiated | Piper Sandler | Overweight |
| Jan-05-24 | Upgrade | BofA Securities | Neutral → Buy |
| Jan-04-24 | Initiated | Wedbush | Outperform |
| Nov-16-23 | Initiated | Raymond James | Outperform |
| Feb-28-23 | Upgrade | JP Morgan | Neutral → Overweight |
| Dec-14-22 | Initiated | Needham | Buy |
| Oct-21-22 | Initiated | Oppenheimer | Outperform |
| May-20-22 | Initiated | BofA Securities | Neutral |
| Mar-01-22 | Upgrade | Stifel | Hold → Buy |
| Sep-23-21 | Initiated | Stifel | Hold |
| Aug-12-21 | Downgrade | Goldman | Buy → Neutral |
| May-18-21 | Initiated | Goldman | Buy |
| May-21-20 | Initiated | H.C. Wainwright | Buy |
| Mar-09-20 | Initiated | Cowen | Outperform |
| Mar-09-20 | Initiated | Guggenheim | Buy |
| Mar-09-20 | Initiated | JP Morgan | Neutral |
View All
Revolution Medicines Inc Stock (RVMD) Latest News
Revolution Medicines (RVMD) Wins FDA Review Milestone For Daraxonrasib In Pancreatic Cancer - Yahoo Finance
Can Revolution Medicines (RVMD) Justify Its Valuation On Daraxonrasib Survival Data? - Yahoo Finance Singapore
‘Pharma Bro’ Martin Shkreli Defends Revolution Medicines’ Pancreatic Cancer Study Data: ‘Progress Compounds’ - Stocktwits
Revolution Medicines, Inc. (RVMD) stock price, news, quote and history - Yahoo Finance UK
Revolution Medicines (RVMD) Is Up 5.3% After FDA Priority Review For Pancreatic Cancer Drug Approval Bid - simplywall.st
Revolution Medicines Inc. R (42Z.DU) Q4 FY2025 earnings call transcript - Yahoo Finance
Bragar Eagel & Squire, P.C. Reminds Erasca, Inc. (ERAS) Investors that a Class Action Lawsuit Has Been Filed Against Erasca and Encourages Investors to Contact the Firm Before August 10th - GlobeNewswire Inc.
FDA Accepts RVMD's Filing for Daraxonrasib in Pancreatic Cancer - Zacks Investment Research
RVMD Maintains Rating by Wedbush -- Price Target Raised to $192.10 - GuruFocus
FDA panel confronting peptide controversy - STAT
symbol__ Stock Quote Price and Forecast - CNN
RVMD|Revolution Medicines Inc|Price:189.500|Chg%:+0.750 - TradingKey
Revolution Medicines (RVMD) Sees FDA Acceptance for Daraxonrasib Review - GuruFocus
Revolution Medicines' Application for Pancreatic Cancer Treatment Accepted by FDA - Moomoo
Revolution Medicines' New Drug Application For Daraxonrasib Accepted For Review By U.S. FDA - TradingView
FDA accepts review of Revolution Medicines' dar... - Pluang
Oral Investigational Medicine for Pancreatic Cancer Is Accepted for FDA Review - Stock Titan
Revolution Medicines, Inc. (RVMD) Q3 2024 Earnings ReportResults, Call & Slides - TipRanks
(RVMD) Price Dynamics and Execution-Aware Positioning - Stock Traders Daily
RVMD Maintained by Needham -- Price Target Raised to $236 - GuruFocus
Revolution Medicines, Inc. (RVMD) Stock Analysis: Why Analysts Are Bullish on This $39.58 Billion Biotech Innovator - DirectorsTalk Interviews
Is Revolution Medicines (RVMD) A Bargain As Daraxonrasib Trial Results Lift Its Outlook? - simplywall.st
Why is Revolution Medicines (RVMD) up 9.3% since last earnings report? - MSN
Anti-Cancer Upstart’s Stock Surges 125% This Year as Billionaire Druckenmiller Builds Large Position - NAI500
Erasca: A Credible Rival To Revolution's Daroxonrasib, At A Cheaper Price Point (ERAS) - Seeking Alpha
Revolution Medicines Gains as Investors Continue to Digest Clinical and Regulatory Momentum - Quiver Quantitative
All eyes on data on Biogen’s tau therapy - STAT
Revolution Medicines, Inc. (RVMD) Stock Analysis: A Biotech Titan with a Promising 7.17% Upside - DirectorsTalk Interviews
How Investors Are Reacting To Revolution Medicines (RVMD) Pancreatic Cancer Data For RAS G12D Inhibitor - simplywall.st
Truist reiterates Buy on Revolution stock, keeps $210 target By Investing.com - Investing.com India
Truist Financial Maintains Revolution Medicines(RVMD.US) With Buy Rating - Moomoo
Revolution Medicines Price Target Raised to $235.00/Share From $205.00 by Guggenheim - Moomoo
RVMD Maintained by Guggenheim -- Price Target Raised to $235 - GuruFocus
Revolution Medicines Is Maintained at Buy by Guggenheim - Moomoo
Better Growth Buy: Axsome vs Revolution Medicines - The Motley Fool
Revolution Medicines (RVMD) Wins Faster Reviews, Is The Valuation Already Too Rich? - simplywall.st
EMA’s Review of Daraxonrasib in PDAC Accelerated Under Phased Review Process - CancerNetwork
Drug that could extend lives of Canadians with pancreatic cancer remains out of reach for patients - The Globe and Mail
Revolution Medicines (RVMD) Holds Steady Near Resistance—Consolidation or Catalyst Ahead?Vol Target Rebalance - dars.gov.et
EMA speeds up review of Revolution Medicines' d... - Pluang
Revolution Medicines Says EMA Begins Phased Review of Daraxonrasib for Pancreatic Cancer as FDA NDA Submission Nears Completion - Quiver Quantitative
European Medicines Agency Expedites Assessment of Revolution Medicines’ Daraxonrasib Under Phased Review Process - The Manila Times
Revolution Medicines, Inc. - Via Ritzau
EMA fast-tracks Revolution Medicines' pancreatic cancer drug review - Stock Titan
Revolution Medicines wins EU fast track review for cancer drug - Seeking Alpha
EMA fast-tracks review of Revolutions' experimental pancreatic cancer pill - Reuters
Pulling the plug on cancer: Agios Pharmaceuticals, Revolution Medicines, and Vidac Pharma - Stockhouse
There's a Revolution in Cancer. But Can Big Pharma Afford It? -- Heard on the Street -- WSJ - Moomoo
Revolution Medicines stock hits all-time high at 193.12 USD By Investing.com - Investing.com South Africa
RVMD Reiterates by HC Wainwright & Co. -- Price Target Maintained at $195 - GuruFocus
Revolution Medicines Inc Stock (RVMD) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.13%
0.27%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):